Filing Flows › Acadia Pharmaceuticals (ACAD) › How it makes money
How Acadia Pharmaceuticals (ACAD) makes money
Acadia Pharmaceuticals (ACAD) made $342M of revenue in the third quarter 2026 (Q3 2026), +23% from a year earlier. Nuplazid brought in $202M (59%); Daybue brought in $140M (41%). Of every dollar of revenue, 21¢ was left as operating profit, 16¢ was left as net earnings.
Drawing the Sankey…
Revenue by segment, Q3 2026
| Segment | Revenue | Share | Q/Q | Y/Y |
|---|---|---|---|---|
| Nuplazid | $202M | 59.1% | — | +14% |
| Daybue | $140M | 40.9% | — | +39% |
Where each dollar of revenue goes
| Line | Q3 2026 | % of revenue |
|---|---|---|
| Revenue | $342M | 100.0% |
| Operating profit | $71.7M | 21.0% |
| Income tax | $26.9M | 7.9% |
| Net earnings | $53.5M | 15.6% |
| Operating cash flow | $11.5M | 3.4% |
| Free cash flow | $10.3M | 3.0% |
Revenue, quarter by quarter
| Quarter | Revenue | Y/Y |
|---|---|---|
| Q3 2026 | $342M | +23% |
| Q2 2026 | $308M | +16% |
| Q1 2026 | $268M | +10% |
| Q4 2025 | $284M | +9% |
| Q3 2025 | $279M | +11% |
| Q2 2025 | $265M | +9% |
| Q1 2025 | $244M | +19% |
From Acadia Pharmaceuticals' 10-Q filed Nov 5, 2026 (on EDGAR).
Questions
How does Acadia Pharmaceuticals make money?
Acadia Pharmaceuticals (ACAD) made $342M of revenue in the third quarter 2026 (Q3 2026), +23% from a year earlier. Nuplazid brought in $202M (59%); Daybue brought in $140M (41%). Of every dollar of revenue, 21¢ was left as operating profit, 16¢ was left as net earnings.
What is Acadia Pharmaceuticals' biggest business?
Nuplazid: $202M in the third quarter 2026, 59% of revenue, +14% from a year earlier.
What is Acadia Pharmaceuticals' profit margin?
Net earnings were $53.5M, 15.6% of revenue, in the third quarter 2026; the operating margin was 21.0%.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.